# 健康創新與經濟變動在全球掀起波瀾。

*biotech, business · news · 2026-05-05 · Devdiscourse*

## Key points

- Mirum Pharmaceuticals 的罕見肝病藥物在中期臨床研究中達成關鍵里程碑。
- 瑞士生技公司在嚴峻市場環境下，私募投資較 2024 年增加 38%。
- GMR Solutions 目標估值 50 億美元，計劃在美國進行首次公開募股。
- 一艘郵輪爆發漢他病毒，導致三名乘客死亡。

Health innovations and economic shifts are making waves globally. Mirum Pharmaceuticals has reached a significant milestone with its rare liver disease drug in a mid-stage study. Meanwhile, Swiss biotechs are benefiting from a pivot towards private funding amid challenging capital markets, revealing a 38% increase in private investment compared to 2024. In investment news, multiple pharmaceutical and biotech companies are preparing for substantial IPOs. Emergency medical services provider GMR Solutions eyes a $5 billion valuation in the U.S., while China's Impact Therapeutics and Boston-based Odyssey Therapeutics are also launching IPOs in Hong Kong and the U.S. respectively, signaling strong investor interest. On a critical note, health alerts have arisen with a hantavirus outbreak on a cruise ship resulting in three deaths. Additionally, legal tussles over mail-order access to mifepristone continue in the U.S., reflecting the ongoing debates surrounding reproductive health policies. (With inputs from agencies.)

**Companies:** Mirum Pharmaceuticals, GMR Solutions, Impact Therapeutics, Odyssey Therapeutics
**Countries:** United States, China

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3896876-global-health-innovations-and-challenges-from-ipos-to-outbreaks)

---

Canonical: https://newsio.io/zh-TW/n/0c2409c9-78f2-4985-a451-7489ebf64a34/mirum-pharmaceuticals
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works